uniQure (QURE) Cash from Financing Activities (2016 - 2026)
uniQure (QURE) posted quarterly Cash from Financing Activities of $249.1 million for Q2 2026, up 566072.73% year-over-year from N/an in Q2 2025, and up 45193.82% quarter-over-quarter from $550000.0 in Q1 2026.
Analysis
uniQure (QURE) Cash from Financing Activities (2016 - 2026) Analysis & Trends
uniQure's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $249.1 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 566072.73% year-over-year to $249.1 million; the TTM figure through Jun 2026 stood at $584.4 million (up 2659.23% YoY), while the FY2025 annual figure was $415.4 million, up 798.31% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at $249.1 million, up from $550000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $370.1 million in Q2 2023, with the low at -$53.0 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is $393000.0 (2022), against an average of $60.6 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 638067.24% in 2023, then plunged 14267.39% in 2024.
- uniQure's Cash from Financing Activities stood at $601000.0 in 2022, then tumbled by 92.35% to $46000.0 in 2023, then slumped by 14267.39% to -$6.5 million in 2024, then jumped by 137.58% to $2.4 million in 2025, then surged by 10072.15% to $249.1 million in 2026.
- Business Quant data shows QURE's Cash from Financing Activities at $249.1 million in Q2 2026, $550000.0 in Q1 2026, and $2.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 249.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 249.12 Mn |
| Mar 31, 2026 | 550,000.00 |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 332.24 Mn |
| Jun 30, 2025 | 44,000.00 |
| Mar 31, 2025 | 80.67 Mn |
| Dec 31, 2024 | -6.52 Mn |
| Sep 30, 2024 | -53.02 Mn |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | -7.59 Mn |
| Jun 30, 2023 | 370.14 Mn |
| Mar 31, 2023 | 131,000.00 |
| Dec 31, 2022 | 601,000.00 |
| Sep 30, 2022 | 301,000.00 |
| Jun 30, 2022 | 58,000.00 |
| Mar 31, 2022 | 485,000.00 |
| Dec 31, 2021 | 29.89 Mn |
| Sep 30, 2021 | -164,000.00 |
| Jun 30, 2021 | 2.51 Mn |
| Mar 31, 2021 | 62.62 Mn |